Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Masataka Yokode
Based on 3 articles published since 2010
(Why 3 articles?)

Between 2010 and 2020, Masataka Yokode wrote the following 3 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Article [Diagnostic utility of endoscopic ultrasonography elastography and contrast-enhanced harmonic endoscopic ultrasonography in a patient with type 2 autoimmune pancreatitis]. 2018

Yokode, Masataka / Shiomi, Hideyuki / Itai, Ryosuke / Mikami, Sakae / Yamashita, Yukimasa / Nakano, Ryota / Ezaki, Takeshi / Masuda, Atsuhiro / Zen, Yoh. ·Department of Gastroenterology, Kobe City Medical Center West Hospital. · Department of Gastroenterology, Kobe University Graduate School of Medicine. · Department of Diagnostic Pathology, Kobe University Graduate School of Medicine. ·Nihon Shokakibyo Gakkai Zasshi · Pubmed #29887592.

ABSTRACT: A referring hospital diagnosed a 57-year-old man with a pancreatic head mass. The initial endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) was inconclusive because of the small sample size. Endoscopic ultrasonography elastography (EUS-EG) and contrast-enhanced harmonic endoscopic ultrasonography (CE-EUS), conducted at our institute, raised the possibility of mass-forming pancreatitis or autoimmune pancreatitis (AIP). A repeat EUS-FNA revealed inflammatory changes, including a neutrophilic duct injury suggestive of type 2 AIP. The pancreatic lesion responded well to the steroid therapy. The present case suggests that EUS-EG and CE-EUS may be useful for diagnostic exclusion of pancreatic cancers, and the combined use of EUS-EG and CE-EUS, with EUS-FNA, may help characterize inflammatory pancreatic lesions.

2 Article High-grade PanIN presenting with localised stricture of the main pancreatic duct: A clinicopathological and molecular study of 10 cases suggests a clue for the early detection of pancreatic cancer. 2018

Yokode, Masataka / Akita, Masayuki / Fujikura, Kohei / Kim, Mi-Ju / Morinaga, Yukiko / Yoshikawa, Seiichi / Terada, Takuro / Matsukiyo, Hiroshi / Tajiri, Takuma / Abe-Suzuki, Shiho / Itoh, Tomoo / Hong, Seung-Mo / Zen, Yoh. ·Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan. · Department of Gastroenterology and Hepatology, Kobe City Medical Center West Hospital, Kobe, Japan. · Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. · Department of Gastroenterology, Nagaoka Red Cross Hospital, Nagaoka, Japan. · Department of Surgery, Fukuiken Saiseikai Hospital, Fukui, Japan. · Department of Surgery, Toho University Ohashi Medical Center, Tokyo, Japan. · Department of Diagnostic Pathology, Tokai University Hachioji Hospital, Tokyo, Japan. ·Histopathology · Pubmed #29660164.

ABSTRACT: AIMS: This study aimed to identify the pathological features of high-grade PanIN that presents with imaging-detectable abnormalities. METHODS AND RESULTS: Ten cases of isolated, main-duct, high-grade PanIN as the primary clinical presentation were identified. All patients presented with stenosis of the main pancreatic duct, with two being associated with extensive upstream duct dilatation (>5 mm in diameter). Pancreatic juice cytology suggested adenocarcinoma in all seven cases examined. In resected specimens, high-grade PanIN was present chiefly in the main pancreatic duct, with longitudinal extension ranging between 3 and 40 mm in length (median = 18 mm). In four cases, in which hypoechoic or hypovascular masses were observed on imaging, radiopathology correlations suggested that they represented parenchymal atrophy and subsequent fibrosis around affected ducts, but not invasive malignancy. On immunohistochemistry, the loss of p16 expression was found in five (50%), p53 overexpression in two (20%) and loss of SMAD4 expression in none (0%). KRAS mutations were detected in nine cases, with two dominant clones being found in three by ultrasensitive droplet digital polymerase chain reaction, suggesting the genetic heterogeneity of dysplastic cells composing individual lesions. Mutant GNAS was also observed in one case. CONCLUSIONS: Isolated high-grade PanIN may present with pancreatic duct stenosis. Therefore, intensive investigations including pancreatic juice cytology will be required for patients with unexplained pancreatic duct stenosis. The abnormal expression of p53 and SMAD4 is infrequent, while GNAS may be mutated in premalignant lesions mainly affecting the main pancreatic duct, similar to KRAS.

3 Article A case report of mixed acinar-endocrine carcinoma of the pancreas treated with S-1 chemotherapy: Does it work or induce endocrine differentiation? 2017

Yokode, Masataka / Itai, Ryosuke / Yamashita, Yukimasa / Zen, Yoh. ·aDepartment of Gastroenterology and Hepatology, Kobe City Medical Center West Hospital bDepartment of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan. ·Medicine (Baltimore) · Pubmed #29137060.

ABSTRACT: RATIONALE: Acinar cell carcinomas (ACCs) and mixed acinar-endocrine carcinomas (MAECs) of the pancreas are rare, accounting for only 1% of pancreatic tumors. Although both typically present at an advanced stage, chemotherapeutic regimes have not yet been standardized. PATIENT CONCERNS: A 65-year-old man presented with a large mass in the pancreatic tail with multiple liver metastases. DIAGNOSIS, INTERVENTIONS, OUTCOMES: He was initially treated with gemcitabine for suspected ductal carcinoma of the pancreas, but no response was observed. S-1, administered as second-line chemotherapy, showed an approximately 38% reduction in the size of the primary tumor and metastatic deposits with therapeutic effects being maintained for 12 months. When the tumor progressed again, he underwent a percutaneous liver biopsy, which led to the diagnosis of MAEC. Combination therapy with cisplatin and etoposide targeting the endocrine component was administered, and this was based on the endocrine component potentially being less sensitive to S-1 than the ACC element. However, therapy was stopped due to the development of neutropenia, and the patient is currently receiving best supportive care. LESSONS: Given the previous studies suggested that S-1 is more effective for ACCs than gemcitabine, MAECs may also respond to S-1 chemotherapy, similar to ACCs. Another potential interpretation is that S-1 was effective when the condition was ACC, and eventually showed decreased effectiveness when the condition shifted to MAEC. Future studies are needed to conclude whether S-1 chemotherapy truly works against MAECs or induces endocrine differentiation in ACCs as a part of the drug-resistance process.